B-type Natriuretic Peptide (BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF)
description
Transcript of B-type Natriuretic Peptide (BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF)
B-type Natriuretic Peptide(BNP) in the Diagnosis of
Acute Congestive Heart Failure (CHF)
Scott M Silvers, MD
1st Annual Pan American Conference
Emergency Medicine Clinical Policies
November 6 – 7, 2003
Lecture Outline
• Introduction to BNP
• Case
• Critical Question
• Literature Search
• Critical Literature Evaluation
• Evidence-based Recommendations
Introduction to BNP
• 32-aa polypeptide• Found in heart ventricles• Produced with ventricular
stretch and volume• Results in vasodilation,
natriuresis, diuresis, and reduced preload
• Increases with worsening heart failure
Introduction to BNP
Maisel AS, et al. N Engl J Med. 2002;347(3):161-167.
Introduction to BNP
Morrison LK, et al. J American Coll of Card. 2002;39(2):202-209.
CaseCurrent History:
Ms. GM is a 76 yo woman with a history only of obstructive lung disease who presents to the emergency department with 2 days of progressively worsening shortness of breath.
Physical ExaminationT= 37°C HR= 110 BP= 170/90 RR= 40 SO2 (air)= 87%She is unable to speak long sentences.Neck veins: difficult to assessHeart: difficult to hear over her lung soundsLungs: diffuse wheezing with decreased breath sounds and rales at the basesAbdomen: normalExtremities: warm with moderate pitting edema
Chest X-ray
Critical Question
What is the utility of a B-type natriuretic peptide (BNP) measurement in the diagnosis of congestive heart failure among patients
presenting to an emergency department with shortness of breath?
Curiosity Poll
How many people have a BNP assay available to them where they practice?
Literature Search
• Medline January 1995 – Present• Keywords
– “Brain natriuretic peptide”, “B-type natriuretic peptide,” “B natriuretic peptide,” or “BNP”
1, 745 papers
• Limits– Human subjects, clinical trials, meta-analyses 164 papers
Literature Search
• Abstracts of clinical studies reviewed– Patients presenting with shortness of breath to
“acute care” centers 5 papers
– Reviews and clinical policies 2000 - present (references crosschecked)
Typical Study Methodology
Inclusion Criteria• Adult patients presenting to an “acute care” facility• Primary complaint shortness of breath
Exclusion Criteria• Obvious non-CHF cause of shortness of breath• Renal Failure• Acute myocardial infarction
Typical Study Methodology
• Evaluation by an emergency physician• Assessment of clinical probability of CHF• BNP assay sent
– Results not revealed to emergency physician
• Patient treated and dispositioned• Physician team blinded to BNP
measurement assign final diagnosis after evaluation of case
Typical Study Methodology
CHF “Gold Standard”
• Clinical findings• Chest x-ray • Echocardiography• Nuclear cardiology• Cardiac Catheterization• Framingham and NHANES scores• Clinical response to therapies
Critical Literature Evaluation:BNP in Diagnosing CHF
• 5 published studies to date– 2 report data from the same sample
Critical Literature Evaluation:BNP in Diagnosing CHF
Study Year N DesignCHF
PrevalenceStudy Grade
Davis, et al 1994 52Prospective
Unblinded62% 3
Dao, et al
(Maisel)2001 250
Prospective
Unblinded39% 3
Morrison, et al
(Maisel)2002 321
Prospective
Blinded42% 2
Maisel, et al
“Breathing Not Properly” (BNP)
2002 1586Prospective
Blinded
Multinational47% 1
McCullough, et al
(Maisel)2002 1,538
Prospective
Blinded
Multinational47% 2
Critical Literature Evaluation:BNP in Diagnosing CHF
Maisel et al, (NEJM 2002)
• Prospective, multinational; N = 1,586• All “clinical risk” patients evaluated as one sample• BNP < 22 pmol/L (100 pg/ml) for detecting CHF
Sensitivity = 90%Specificity = 76% NPV = 89% PPV = 79%
• BNP < 11 pmol/L (50 pg/ml) for detecting CHFSensitivity = 97%Specificity = 62% NPV = 96% PPV = 71%
• Study Grade = 1
Critical Literature Evaluation:BNP in Diagnosing CHF
McCullough et al, (Circulation 2002)• Prospective, multinational; N = 1,538• Excluded 48 patients without “clinical risk” assessement• BNP < 22 pmol/L (100 pg/ml)• “Low and Intermediate” clinical probability (0 – 79%)
Sensitivity = 94%Specificity = 70% NPV = 93% PPV = 74%
• “High” clinical probability (80 – 100%)Sensitivity = 49%Specificity = 96% NPV = 68% PPV = 91%
• Study Grade = 2 (Post-study Analysis)
Critical Literature Evaluation
StudyBNP Cutoff
pmol/L
Sens
%
Spec
%
PPV
%
NPV
%Comments
Davis,
et al22
(100 pg/ml)93 90 93 90
•Small sample size
•Not blinded: ED Dx or BNP
•Nuclear study to assess EF
•Not consecutive patients
Dao, et al
(Maisel)18
(80 pg/ml)98 92 90 98
•Small sample size
•Not blinded: ED Dx or BNP
•VA patients (Male)
•Not consecutive patients
Morrison,
et al
(Maisel)
21(94 pg/ml)
98 86 98 83•Moderate sample size
•VA patients (95% Male)
•Not blinded to ED Dx
Critical Literature Evaluation
StudyBNP Cutoff
pmol/L
Sens
%
Spec
%
PPV
%
NPV
%Comments
Davis,
et al22
(100 pg/ml)93 90 93 90
•Small sample size
•Not blinded: ED Diagnosis or BNP
•Nuclear study to assess EF
•Not consecutive patients
Dao, et al
(Maisel)18
(80 pg/ml)98 92 90 98
•Small sample size
•Not blinded: ED Diagnosis or BNP
•VA patients (Male)
•Not consecutive patients
Morrison,
et al
(Maisel)
21(94 pg/ml)
98 86 98 83•Moderate sample size
•VA patients (95% Male)
•Not blinded to ED Dx
Critical Literature Evaluation
Study
BNP
Cutoff
pmol/L
Clinical CHF
Prob %
Sen
%
Spec
%
PPV
%
NPV
%Comments
Maisel
et al
22(100 pg/ml)
All 90 76 79 89
•Large sample size
•Not consecutive patients11(50 pg/ml)
97 62 71 96
McCullough
et al
(Maisel)
22(100 pg/ml)
80--100 49 96 91 68 •Excluded 3% without clinical CHF assessment
•Not consecutive patients0--79 94 70 74 93
Critical Literature Evaluation
Maisel AS, et al. N Engl J Med. 2002;347(3):161-167.
Critical Literature Evaluation
• Possible Limitation of BNP– Among rats given acute CHF, BNP may take
over 1 hour to rise.
Nakagawa O, et al. J Clin Invest. 1995;96:1280-1287.
Evidenced-based Recommendations
Includes• Patients presenting to an emergency department• Primary complaint shortness of breath
Excludes• Obvious non-CHF cause of shortness of breath• Renal Failure• Acute myocardial infarction
Evidenced-based Recommendations
Level A Recommendations
• A BNP < 11 pmol/L (50 pg/ml) may be used to help rule-out the diagnosis of congestive heart failure when the diagnosis is uncertain. (Probability < 4%).
Evidenced-based Recommendations
Level B Recommedations• Among low and intermediate “clinical probability”
patients, a BNP < 22 pmol/L (100 pg/ml) may be used to help rule-out the diagnosis of congestive heart failure. (Probability < 5%)
• Among patients without a history of CHF, a BNP > 88 pmol/L (400 pg/ml) may be used to rule-in the diagnosis of CHF when the diagnosis is uncertain. (Probability > 95%)
• A BNP > 220 pmol/L (1,000 pg/ml) may be used to rule-in the diagnosis of acute CHF among patients presenting with a history of CHF. (Probability > 95%)
Evidenced-based Recommendations
Level C Recommendations
• When evaluating a patient who presents with possible CHF within 1 hour from symptom onset, use caution in the interpretation of a low BNP level as BNP may take over 1 hour to rise.
Key References• Davis M, et al. Plasma brain natriuretic peptide in assessment of acute
dyspnea. Lancet. 1994;343:440-444.• Dao Q, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive
heart failure in an urgent-care setting. J Amer Coll Card. 2001;37(2):379-385.• Morrison LK, et al. Utility of a rapid B-natriuretic peptide assay in
differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Amer Coll Card. 2002;39(2):202-209.
• Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Eng J Med. 2002;347(3):161-167.
• McCullough PA, et al. B-typenatriuretic peptide and clinical judgement in emergency diagnosis of heart failure – Analysis from breathing not properly (BNP) multinational study. Circulation. 2002;106:416-422.
• Nakagawa O, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. J Clin Invest. 1995;96:1280-1287.
The End